An FDA advisory committee voted unanimously that Forest Laboratories (FRX) has demonstrated the safety and effectiveness of Memantine to treat moderate to severe Alzheimer's disease (AD). Committee members
Read the full 282 word article
User Sign In
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury